A recent study compared three clinical criteria for rheumatoid arthritis (RA) in patients using certolizumab, assessing the predictability of treatment non-response. Researchers found Clinical Disease Activity Index measurement at three months may predict patient outcomes at 12 months…
Adding certolizumab pegol to background medication is better than adding a placebo for patients with active nonradiographic axial spondyloarthritis, according to a new study…
Certolizumab pegol has been approved in Canada for treating adults with plaque psoriasis. The U.K. has also issued its final guidance for the treatment’s use…
Certolizumab pegol is now FDA approved to treat adults with active non-radiographic axial spondyloarthritis…
On the basis of data from multiple clinical trials, the FDA has approved certolizumab pegol for treating moderate to severe plaque psoriasis…
In a Phase 3 study, ixekizumab proved safe and effective to treat adults with ankylosing spondylitis (AS)…
In the EU, certolizumab pegol has been approved for use in pregnant and nursing women with chronic rheumatic disease…
Certolizumab pegol has proved safe and effective for treating patients with plaque psoriasis in a Phase 3 clinical trial…
In a small-scale study, researchers found that no, or minimal amounts of, certolizumab pegol transfers from mothers taking the drug to nursing infants…
NEW YORK (Reuters Health)—There is minimal to no transfer of the tumor necrosis factor (TNF) inhibitor certolizumab (Cimzia) from plasma to breast milk, according to a new study. “These findings are reassuring” and imply that continuing certolizumab treatment is compatible with breastfeeding, Dr. Megan Clowse of Duke University School of Medicine in Durham, North Carolina,…